A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects

NCT01677741 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

85

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms, Brain

Interventions

DRUG: Dabrafenib

Sponsor

Novartis Pharmaceuticals